Evidence map›Paper›PMID 27075261›Full record

ReviewNature reviews. Gastroenterology & hepatology2016

Experimental models of hepatitis B and C - new insights and progress.

Emmanuel Thomas, T Jake Liang

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 85 citations in OpenAlex.

  1. State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  2. Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025
    Review
  3. Building up a model family for inflammations.Journal of mathematical biology · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Frontiers in microbiology · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Emmanuel ThomasSchiff Center for Liver Diseases and Sylvester Cancer Center, Room PAP514, Papanicolaou Building, 1550 NW 10th Avenue, Miami, Florida 33136, USA.
T Jake LiangLiver Diseases Branch, NIH, Building 10-9B16, Bethesda, Maryland 20892-1800, USA.
National Institutes of Health · USSylvester Comprehensive Cancer Center · US

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE · 2007 to 2026
$33.8M
Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And PersistenceZIADK054500 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$20.3M
Molecular Approaches To Vaccine Development For Hepatitis CZIADK054503 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$18.9M
Therapy, Vaccine and Model Development in Viral Hepatitis and Liver DiseasesZIADK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$17.5M
Studies of HCV Infection, Vaccine Development and HCV-Host interactionsZIADK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2022
$12.0M
A MULTIFACETED APPROACH TO STUDY TISSUE AND CELL TYPE SPECIFIC MOLECULAR MECHANISMS OF THE HOST RESPONSE TO ACUTE/CHRONIC VIRAL INFECTIONR35GM124915 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Emmanuel Thomas · 2017 to 2026
$3.9M
The Genetics of Disease Progression and Treatment Response in Hepatitis CZIADK054511 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2017
$3.8M
Miami Clinical and Translational Science InstituteKL2TR000461 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$2.1M
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK054500Intramural NIH HHS ZIA DK054503Intramural NIH HHS ZIA DK054504Intramural NIH HHS ZIA DK054505Intramural NIH HHS ZIA DK054511NCATS NIH HHS KL2 TR000461NIAID NIH HHS L30 AI107941NIAID NIH HHS P30 AI073961NIGMS NIH HHS R35 GM124915
6 · The paper itself

Abstract

Viral hepatitis is a major cause of morbidity and mortality, affecting hundreds of millions of people worldwide. Hepatitis-causing viruses initiate disease by establishing both acute and chronic infections, and several of these viruses are specifically associated with the development of hepatocellular carcinoma. Consequently, intense research efforts have been focusing on increasing our understanding of hepatitis virus biology and on improving antiviral therapy and vaccination strategies. Although valuable information on viral hepatitis emerged from careful epidemiological studies on sporadic outbreaks in humans, experimental models using cell culture, rodent and non-human primates were essential in advancing the field. Through the use of these experimental models, improvement in both the treatment and prevention of viral hepatitis has progressed rapidly; however, agents of viral hepatitis are still among the most common pathogens infecting humans. In this Review, we describe the important part that these experimental models have played in the study of viral hepatitis and led to monumental advances in our understanding and treatment of these pathogens. Ongoing developments in experimental models are also described.

Indexed as

Disease Models, AnimalAnimalsAntiviral AgentsCarcinoma, HepatocellularCell LineDNA, ViralForecastingHepacivirusHepatitis B, ChronicHepatitis B virusHepatitis C, ChronicHepatocytesHumansLife Cycle StagesLiver NeoplasmsPrimatesAntiviral AgentsDNA, Viral

Identifiers

PMID27075261
PMCPMC5578419
OpenAlexW2340954406

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.